Lonza : Announces Results of the 2020 Annual General Meeting All Motions Proposed by Board of Directors Accepted

Switzerland - Lonza Group Ltd hosted its Annual General Meeting, led by the Chairman of the Board of Directors, Albert M. Baehny.

Due to the ongoing COVID-19 pandemic, no shareholders were admitted to attend the Annual General Meeting in person. Lonza had previously recommended that shareholders delegate their votes to the independent proxy on 20 March 2020. The independent proxy represented 100% of the 44,965,404 votes represented at the Annual General Meeting.

The Board members standing for re-election (Albert M. Baehny, Werner Bauer, Angelica Kohlmann, Christoph Mader, Barbara Richmond, Jurgen Steinemann and Olivier Verscheure) were all elected for a further term in office of one year. Patrick Aebischer and Margot Scheltema did not stand for re-election.

The Annual General Meeting re-elected Albert M. Baehny as Chairman of the Board of Directors for a term in office of one year. The shareholders also elected Dorothee Deuring and Moncef Slaoui as new members of the Board and Angelica Kohlmann, Christoph Mader and Jurgen Steinemann as the three acting members of the Nomination and Compensation Committee.

The shareholders supported all other motions proposed by the Board of Directors, including among others the acceptance of the remuneration report and the binding votes on the compensation for the Board of Directors and the Executive Committee.

A dividend of CHF 2.75 per share, as proposed by the Board of Directors and accepted by the shareholders, will be paid out starting from 5 May 2020. Fifty percent of this dividend will be paid out as repayment from reserves from capital contributions, without deduction of Swiss withholding tax, in accordance with Article 5, paragraph 1 bis of the Federal Law on Withholding Tax.

Contact:

Dr. Kristin Koehler

Tel: [phone]

Email: [e-mail]

About Lonza

At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors. We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment. Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion.

(C) 2020 Electronic News Publishing, source ENP Newswire